India hit a milestone of administering 100 crore (1 billion) vaccination doses against Covid-19 on October 21. While it is indeed a great achievement, India has a long way to go before we meet the government-set target of administering two doses of vaccines each to 100 crore people by the year end. The challenges are many: only 30% of that target population has been covered so far. Our vaccine supplies have so far been centered on two brands Covishield and Covaxin. Our weekly rate of vaccinations has been hugely fluctuating. The vaccine distribution has been population centric, not infection centric. Also there is no clarity on when the younger ones, children below 18, will begin to get vaccines.
Top Stories
India's Vaccine Roll-out
Next target for Covid vaccine: 200 crore; How soon?
100 crore shots and rising.
More FromIndia's Vaccine Roll-out
Pace of Covid vaccination pacifies critics
The Omicron wave has not changed matters as studies and clinical evidence shows vaccination offers strong protection against serious disease
Pfizer oral pill for Covid-19 gets US FDA approval
Company to increase production of Paxlovid from 80 million to 120 million courses of treatment in 2022; plans to launch worldwide with voluntary licenses to other manufacturers
Common global rules must for new Covid drug trials: Adar Poonawalla
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19
Covid 19 syringe shortage threat averted as Haryana eases pollution curbs
Factories allowed to run eight hours a day, five days a week and use diesel genset only in case of power outages.
More FromIndia's Vaccine Roll-out
Pace of Covid vaccination pacifies critics
The Omicron wave has not changed matters as studies and clinical evidence shows vaccination offers strong protection against serious disease
Pfizer oral pill for Covid-19 gets US FDA approval
Company to increase production of Paxlovid from 80 million to 120 million courses of treatment in 2022; plans to launch worldwide with voluntary licenses to other manufacturers
Common global rules must for new Covid drug trials: Adar Poonawalla
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19
Covid 19 syringe shortage threat averted as Haryana eases pollution curbs
Factories allowed to run eight hours a day, five days a week and use diesel genset only in case of power outages.